FARN Faron Pharmaceuticals Oy

TIDMFARN

Faron Pharmaceuticals Oy

23 November 2020

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron Pharmaceuticals to Participate in Upcoming Investor Conferences

TURKU - FINLAND, 23 November 2020 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company , today announced that management will participate in the following virtual investor conferences:

   --    32nd Annual Piper Sandler Virtual Healthcare Conference 

Pre-recorded fireside chat available on-demand starting Monday, 23 November 2020 at 10:00 a.m. ET

   --    3rd Annual Evercore ISI HealthCONx Conference 

Fireside Chat on Wednesday, 2 December 2020 at 8:25 a.m. ET

Audio webcasts of the presentations will be available in the "Investors" section on Faron's website at https://www.faron.com/investors

ENDS

For more information please contact:

Stern Investor Relations, Inc.

Julie Seidel, Naina Zaman

Phone: +(1)212 362 1200

Email: faron@sternir.com

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFESEFEESSEFF

(END) Dow Jones Newswires

November 23, 2020 02:30 ET (07:30 GMT)

Grafico Azioni Faron Pharmaceuticals Oy (LSE:FARN)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Faron Pharmaceuticals Oy (LSE:FARN)
Storico
Da Apr 2023 a Apr 2024